Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Nov 02, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	2,629	$573.47	553,511
May 21, 2020	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Open market or private sale of non-derivative or derivative security	2,610	$573.55	313,966
Apr 20, 2020	LAROSA JOSEPH J EVP General Counsel and Secret Trans History: 181	EVP General Counsel and Secret	Form 4	Open market or private sale of non-derivative or derivative security	577	$573.59	14,438
Aug 14, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Open market or private sale of non-derivative or derivative security	2,717	$573.64	23,183
Nov 02, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	2,693	$574.55	550,818
Aug 11, 2015	POON CHRISTINE A Director Trans History: 60	Director	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	223	$574.57	902
May 12, 2020	SCHLEIFER LEONARD S Director, President & CEO Trans History: 404	Director, President & CEO	Form 4	Open market or private sale of non-derivative or derivative security	4,390	$574.59	479,061
May 21, 2020	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Open market or private sale of non-derivative or derivative security	2,622	$574.69	311,344
Aug 02, 2021	RYAN ARTHUR F Director Trans History: 524	Director	Form 4	Open market or private sale of non-derivative or derivative security	13	$574.70	23,474
Aug 14, 2015	Powchik Peter SVP Clinical Development & Reg Trans History: 208	SVP Clinical Development & Reg	Form 4	Open market or private sale of non-derivative or derivative security	900	$574.75	22,283

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media